Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAM166A, pseudogene (Ensembl: ENSG00000277099) is a genomic DNA segment that shares high sequence similarity with the protein-coding gene Family with sequence similarity 166 member A (FAM166A) but is classified as a pseudogene because it has mutations or structural differences preventing it from being translated into a functional protein[5][6]. Pseudogenes often result from duplication or retrotransposition events and may lack regulatory sequences, have truncated exons, or harbor mutations such as frameshifts or premature stop codons, rendering them nonfunctional at the protein level[5][1]. Some pseudogenes participate in transcription and can produce non-coding RNAs that may play roles in gene regulation (for example, by acting as competing endogenous RNAs, miRNA sponges, or sources of small interfering RNAs)[1][3][7]. However, there is no evidence that FAM166A, pseudogene acts as a therapeutic target, produces protein, or has direct clinical relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 166 member A, pseudogene (FAM166A, pseudogene).